Takeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1

2026-08-06T10:29:00

Takeda logo

Source:

FDA’s authorisation addresses the condition’s full symptom burden instead of just symptomatic relief.

The US Food and Drug Administration (FDA) has approved Takeda’s Orzeyful (oveporexton) as the first medicine to directly target the loss of orexin signalling that causes Narcolepsy Type 1. It also addresses…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member